- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02165904
Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI
Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in Patients Suffering Incomplete Spinal Cord Injury (SCI)
The study goes on 24 months, with recruiting, treatment and follow period for all patients. The first day for each patient will be the first cellular administration. 3 doses will be administrated every 3 months from first dose.
When the clinical trial finishes, it will be done a completed check of all obtained parameters.
연구 개요
상세 설명
It is a clinical trial phase I, single center, non-randomized, uncontrolled, open prospective follow-up of a cohort of patients with chronic spinal cord injury (SCI) .10 patients will be included with this injury.
Primary objective: Analyze the possible clinical efficacy of administration of main adult mesenchymal autologous cells expanded "in vitro" in patients with incomplete and chronically established SCI.
Secondary objectives: Confirm the safety of treatment, and study possible changes in the cerebrospinal fluid (CSF) levels (Brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), Nerve Growth Factor 3 and 4(NT3 and NT4) after subarachnoid administration of BMMC.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Madrid
-
Majadahonda, Madrid, 스페인, 28222
- Hospital Puerta de Hierro
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Incomplete SCI
- Neurological deficit clinically stable at least 12 months prior to treatment, and with a minimum of one-year evolution after SCI.
- Neurophysiological confirmation of incomplete SCI.
- The MRI study that morphologically evaluate the SCI.
- Age between 18 and 70 years
- Thread Men and women will compromise to use anticonceptive issues from first cell´s extraction to 6 months after last cell´s administration.
- Ability to attend clinical follow-up and perform physical therapy through the treatment period.
- Written and signed informed consent, according to the local regulation.
- Hematologic and creatinin parameters, SGOT and SGPT, within the normal range, according to laboratory standards considering that small variations could be accepted based on clinical study team criteria.
Exclusion Criteria:
- A classification in ASIA and FRANKEL clinical scales to evaluate the SCI.
- Neurophysiological records that confirm the complete SCI.
- Age below 18 years or above 70.
- Pregnancy or lactation.
- Malignancy disease diagnosed or treated within the last 5 years.
- Patients with systemic disease that represents and additional risk to treatment.
- Patients with uncertain commitment to follow the physical therapy and clinical visits as well as patient with a negative input in the previous phycological assessment.
- Inability to assess the SCI features through MRI either noise due to spinal stabilization systems or any other cause.
- Patients currently under hematopoietic growth factors treatment or who required or maintained anticoagulation.
- Neurodegenerative disease additional.
- History of substance abuse, psychiatric disease or allergy to the protein products used in the process of cell expansion.
- Positive serology for HIV and syphilis.
- Active Hepatitis B or Hepatitis C.
- With other reason that would consider the patient ineligible for cell therapy according to the investigators judgment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Autologous Mesenchymal Bone Marrow Cell
All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell
|
Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Efficacy-Sensivity Improvement Using the ASIA Score
기간: measure before treatment (baseline visit), 3, 6, 9 and 12 months after surgery
|
Sensitivity improvement was measured using the ASIA (American Spinal Injury Association) scale to measure the Surface sensitivity (LTS), pain sensitivity (PPS), and the degree of motor function in key muscles (MS).
The sum of MS, LTS, and PPS configure total ASIA score.
A minimum possible score is 0 points.
A maximum possible score is 224 points for a patient with normal sensation.
ASIA score was obtained before surgery, and 3, 6, 9 and 12 months after surgery.
Mean and standard deviation for the 10 patients were obtained at all the time points and statistically analyzed.
|
measure before treatment (baseline visit), 3, 6, 9 and 12 months after surgery
|
Efficacy- Changes in Functional Independence Measure Scale
기간: measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
- Changes in Functional Independence Measure scale (NIF scale), score at the beginning, through and the end of the treatment. Ranges score: 18 to 126. Being 18 total patient dependency and 126 total patient independence. |
measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
Efficacy-Change in Barthel Score
기간: measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
- Changes in Barthel score at the beginning, through and the end of the treatment. Ranges score: 0 to 100. Being 0 total patient dependency and 100 total patient independence. |
measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
Efficacy-IANC-SCIFRS Scale
기간: Changes in IANC-SCIFRS scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
|
-Changes in IANC-SCIFRS scale Ranges score: 0 to 48. Being 0 severe degree of disability and 48 normal value. |
Changes in IANC-SCIFRS scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
|
Efficacy-Changes in PENN Score.
기간: measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
- Changes in PENN score at the beginning, through and the end of the treatment Ranges score: 0 to 4. Being 0 absence of spasms and 4 frequency greater than 10 spasms per hour. |
measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
Changes in ASHWORTH Score
기간: measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
- Changes in ASHWORTH score at the beginning, through and the end of the treatment Ranges score: 0 to 4. Being 0 when there isn´t increase in muscle tone when stretching, and 4 when there is rigid affected follow-up in flexion or extension |
measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
Efficacy-Changes in EVA Score
기간: measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
• Changes in EVA score at the beginning, through and the end of the treatment Ranges score: 0 to 10. Being 0 absence of pain and 10 the worst pain. |
measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
Efficacy- Changes in Geffner Score
기간: Changes in Geffner scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
|
changes in Geffner score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period) Ranges score: 0 to 6. Being 0 absence of bladder control and 6 total control of bladder |
Changes in Geffner scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)
|
Efficacy- Changes in NBD Score
기간: measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
changes in NBD score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period) Ranges score: 0 to 47. 0-6 is very minor dysfunction. 7-9 is minor dysfunction. 10-13 is moderate dysfunction; and 14 or more is severe dysfunction. |
measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery
|
Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)
기간: Efficacy-measure before treatment (baseline visit), 6, and 12 months after surgery
|
Changes in the neurophysiological parameters (SSEPs, somatosensory evoked potentials) measured as the number of patients that improved along the study.
|
Efficacy-measure before treatment (baseline visit), 6, and 12 months after surgery
|
Efficacy-Urodynammic in Terms of Detrusor Pressure
기간: Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up
|
Urodynamic studies in terms of detrusor pressure (decrease on detrusor pressure is considered a clinical improvement)
|
Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up
|
Efficacy-Urodynamic Studies Bladder Compliance
기간: measure before treatment (baseline visit), 6 and 12 months after surgery
|
Urodynamic studies in terms of Bladder compliance. Bladder compliance is the result of a mathematical calculation of volume responsible for 1 cm H2O pressure rise measured during a cystometric filling . It gives an indication on how the different mechanisms in the bladder wall react on stretching. It is obvious that compliance figures can vary widely in groups which makes it difficult to define limits of normality. |
measure before treatment (baseline visit), 6 and 12 months after surgery
|
Efficacy-Urodynamic Studies Maximum Cystometric Capacity
기간: Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up
|
Urodynamic studies in terms of Maximum cystometric capacity
|
Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up
|
Efficacy-modification of Magnetic Resonance Imaging (MRI)
기간: before (baseline visit) and at 12 months
|
Number of patients with changes in morphology of injury compared with basal images
|
before (baseline visit) and at 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Adverse Events .
기간: Up to 12 months
|
- The safety will be valued with number of adverse events related with administration of subarachnoid autologous Bone Marrow Expanded Mesenchymal Cells in Incomplete Spinal Cord Injury (SCI).
|
Up to 12 months
|
Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples
기간: Basal and 10 months after the administration
|
Changes in expression of neurotrophins in CSF (CerebroSpinal Fluid) samples obtained previously to first administration of cell therapy, and previously to the last administration, at month 10, in order to study the variability in the expression of neurotrophins along time.
The mean+SD (standard deviation) at each time point was obtained.
The tested neurotrophins were: BDNF.
|
Basal and 10 months after the administration
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Jesús JV Vaquero Crespo, M.D., Hospital Universitario Puerta de Hierro-Majadahonda
간행물 및 유용한 링크
일반 간행물
- Vaquero J, Zurita M. Functional recovery after severe CNS trauma: current perspectives for cell therapy with bone marrow stromal cells. Prog Neurobiol. 2011 Mar;93(3):341-9. doi: 10.1016/j.pneurobio.2010.12.002. Epub 2010 Dec 14.
- Otero L, Zurita M, Bonilla C, Aguayo C, Vela A, Rico MA, Vaquero J. Late transplantation of allogeneic bone marrow stromal cells improves neurologic deficits subsequent to intracerebral hemorrhage. Cytotherapy. 2011 May;13(5):562-71. doi: 10.3109/14653249.2010.544720. Epub 2011 Jan 5.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- CME-LEM2
- 2011-005684-24 (레지스트리 식별자: 2011-005684-24)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
척수 손상에 대한 임상 시험
-
The Second Hospital of Qinhuangdao완전한
-
National Health Service, United KingdomUniversity of Bradford완전한
-
Rennes University Hospital완전한